Cytomx Therapeutics Inc Stock Price, News & Analysis

CytomX Therapeutics (Nasdaq: CTMX) said Sean McCarthy, D.Phil., chief executive officer and chairman, will take part in a fireside chat at the Jefferies Global Healthcare Conference in London on Thursday, November 20, 2025 at 9:00 a.m. GMT.

A live webcast will be available on the company’s Events and Presentations page at www.cytomx.com, and management will be available for one-on-one investor meetings for registered conference attendees.

CytomX Therapeutics (Nasdaq: CTMX) reported Q3 2025 results and a pipeline update on Nov 6, 2025. The company ended Q3 with $143.6 million in cash, cash equivalents and investments and expects runway to Q2 2027. Q3 revenue was $6.0 million versus $33.4 million a year earlier, driven by completion of Bristol Myers Squibb performance obligations and reduced Moderna activity. Operating expense for the quarter was $21.7 million and R&D was $15.3 million.

Pipeline highlights: CX-2051 Phase 1 expansion is ongoing, with projected enrollment of ~100 patients by a planned Phase 1 data update in Q1 2026; a CX-2051 Phase 1b combination with bevacizumab is expected to start in Q1 2026. CX-801 monotherapy biomarker data will be presented at SITC 2025 and supports ongoing combination dosing with KEYTRUDA; combo escalation began in May 2025.

CytomX Therapeutics (Nasdaq: CTMX) will present initial Phase 1 translational biomarker data for CX-801 (PROBODY interferon alpha-2b) at SITC 2025 (Nov 7–9).

Data demonstrate tumor-selective activation of interferon signaling and induction of immune cell populations and interferon-stimulated genes (including PD-1 and PD-L1) in paired tumor biopsies, and are reported as generally well tolerated in patients with metastatic melanoma refractory to prior checkpoint inhibitors. CytomX says these findings support the ongoing Phase 1 combination study of CX-801 with KEYTRUDA, with combination clinical data expected in 2026.

Poster: “Pharmacodynamic Activity of CX-801…” (Abstract 606) on Nov 8, 2025, 5:10–6:35 PM ET. Additional preclinical poster for CX-908 (Abstract 961) on Nov 7, 2025.

CytomX Therapeutics (Nasdaq: CTMX) will report its third quarter 2025 financial results on Thursday, November 6, 2025, after the close of U.S. markets.

The company will host a conference call and live webcast on November 6, 2025 at 5:00 p.m. ET / 2:00 p.m. PT. Participants can access the live webcast via the company’s Events and Presentations page and are advised to register at least 10 minutes before the call. An archived replay of the webcast will be available on the company website.

CytomX Therapeutics (Nasdaq: CTMX) on October 20, 2025 appointed Rachael Lester as Senior Vice President, Chief Business Officer to lead strategy and business development.

The company highlighted Lester’s two decades of experience in corporate strategy, partnerships and capital formation, citing prior roles as chief business officer at Replicate Bioscience, SVP of business development at Harpoon Therapeutics (acquired by Merck), and senior roles at Bruin Biometrics and Onyx Pharmaceuticals. Management said Lester will drive partnering and expand the PROBODY® platform while supporting lead clinical assets CX-2051 and CX-801 aimed at colorectal cancer and melanoma.

CytomX Therapeutics (NASDAQ: CTMX), a leader in masked, conditionally activated biologics, has announced its participation in three major investor conferences this September in New York.

The company will present at the Cantor Global Healthcare Conference (September 4), the H.C. Wainwright Global Investment Conference (September 9), and the Morgan Stanley Global Healthcare Conference (September 10). All presentations will be available via webcast on the company's website, and management will be available for one-on-one meetings with registered conference attendees.

CytomX Therapeutics (NASDAQ:CTMX) provided an update on its Phase 1 study of CX-2051 for colorectal cancer treatment. The CTMX-2051-101 study has successfully enrolled 73 patients across three dose expansion cohorts (7.2 mg/kg, 8.6 mg/kg, and 10 mg/kg Q3W), with approximately 20 patients per dose level.

The company reported a single Grade 5 treatment-related adverse event involving acute kidney injury in a patient with a complex medical history. Following this event, reported to the FDA on July 18, 2025, the Safety Review Committee supported continued study execution. CytomX remains on track to provide a Phase 1 data update in Q1 2026.

CytomX Therapeutics (Nasdaq: CTMX) reported Q2 2025 financial results and significant clinical progress. The company announced positive interim data from Phase 1 study of CX-2051, their first-in-class EpCAM Antibody Drug Conjugate for advanced colorectal cancer, with Phase 2 study initiation planned for 1H 2026. CytomX also initiated combination dose escalation of CX-801 with KEYTRUDA® for advanced melanoma.

Financially, CytomX completed a $100 million common stock offering and ended Q2 2025 with $158.1 million in cash. Revenue was $18.7 million, down from $25.1 million year-over-year. Operating expenses decreased to $19.9 million from $33.6 million in Q2 2024. The company expects its cash runway to extend to Q2 2027.

CytomX Therapeutics (Nasdaq: CTMX), a leader in masked, conditionally activated biologic therapeutics, will release its second quarter 2025 financial results on Thursday, August 7, 2025, after U.S. markets close.

The company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT. Investors can access the live webcast through CytomX's investor relations website and are advised to register at least 10 minutes before the call. A replay will be available on the company's website after the event.